Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study

BACKGROUND: In real-world experience, the number of patients using vedolizumab as first-line biological therapy was low. We aimed to evaluate the effectiveness and safety of vedolizumab in mild-to-moderate Crohn’s disease (CD) biologic-naïve patients. METHODS: We performed a retrospective multicentr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dotti, Adriana Zanoni, Magro, Daniela Oliveira, Vilela, Eduardo Garcia, Chebli, Julio Maria Fonseca, Chebli, Liliana Andrade, Steinwurz, Flavio, Argollo, Marjorie, Carvalho, Nayara Salgado, Parente, Jose Miguel Luz, Lima, Murilo Moura, Parra, Rogério Serafim, Perin, Ramir Luan, Flores, Cristina, Morsoletto, Eloá Marussi, da Costa Ferreira, Sandro, Ludvig, Juliano Coelho, Kaiser Junior, Roberto Luiz, Faria, Mikaell Alexandre Gouvea, Nicollelli, Guilherme Mattioli, Andrade, Adriana Ribas, Queiroz, Natalia Sousa Freitas, Kotze, Paulo Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583759/
https://www.ncbi.nlm.nih.gov/pubmed/37859629
http://dx.doi.org/10.1093/crocol/otad053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583759/
https://www.ncbi.nlm.nih.gov/pubmed/37859629
http://dx.doi.org/10.1093/crocol/otad053

Ejemplares similares